<DOC>
	<DOCNO>NCT00552032</DOCNO>
	<brief_summary>The purpose study determine whether 8 week treatment mometasone furoate nasal spray ( MFNS ) , twice daily , safe effective treat adenoid hypertrophy child .</brief_summary>
	<brief_title>Efficacy Safety Mometasone Furoate Nasal Spray Children With Adenoid Hypertrophy . SNORE Study ( P05155 )</brief_title>
	<detailed_description />
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>Participants parent must demonstrate willingness participate comply study procedure . Parents must sign write informed consent Participants parent must understand able adhere dose visit schedule , agree record symptom severity score , medication time , concomitant medication accurately consistently daily diary Children history adenoid hypertrophy least 3 month response previous medical treatment Baseline adenoid tissue size must grade nasopharyngoscopy examination Grade III IV Adenoid/Choana ( A/C ) Index ( 50 % 100 % obstruction ) Baseline Total Severity Symptoms Score must â‰¥ 8 point ( AM PM ) For inclusion endpoint relate otitis medium effusion ( OME ) , participant must persistent middle ear effusion past 3 month document otoscopic examination , middle ear pressure le 150 mm H2O , Jerger type B flat tympanogram , mildmoderate conductive hearing loss audiometry support diagnosis OME Participants previous surgery hypertrophic adenoid without tympanostomy tube placement Participants treat inhaled systemic corticosteroid within past 1 month Participants Morbid Obesity ( Body Mass Index &gt; 95 percentile chart Centers Disease Control ) Participants accomplish designate washout period prohibit medication Participants use investigational product within last 30 day Participants used antibody allergy past 90 day Participants abnormal physical examination result may affect study evaluation participant safety investigator 's judgment Participants allergic idiosyncratic reaction corticosteroid Participants sign symptom acute chronic bacterial rhinosinusitis Participants upper low respiratory tract sinus infection require antibiotic therapy last dose later 14 day prior screen , viral upper low respiratory infection within 7 day prior screen Participants document immunodeficiency condition Participants nasal structural abnormality , include large nasal polyp mark septum deviation significantly interfere nasal airflow Participants clinically significant metabolic , cardiovascular , neurologic , hematologic , gastrointestinal , cerebrovascular , respiratory disease ( asthma ) , disorder , judgment Investigator , may interfere study evaluation affect participant safety</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>